Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Follow-on Public Offering of Common Stock
January 28, 2015 16:05 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the closing of its previously announced...
Vitae Pharmaceuticals Announces Pricing of Follow-on Public Offering of Common Stock
January 23, 2015 07:20 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the pricing of its follow-on public offering...
Vitae Pharmaceuticals Launches Proposed Follow-on Public Offering of Common Stock
January 20, 2015 08:00 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that it has commenced a proposed follow-on...
Vitae Pharmaceuticals Added to Russell 2000(R) and Russell 3000(R) Indexes
December 23, 2014 08:00 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Dec. 23, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that it has been added to the Russell...
Vitae Pharmaceuticals Among 2014 Best Places to Work in PA
December 08, 2014 08:00 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced it was named one of the 100 Best Places to...
Vitae Pharmaceuticals Reports Third Quarter 2014 Operating and Financial Results
November 12, 2014 16:05 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the...
Vitae Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
November 12, 2014 08:00 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief...
Vitae Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 12, 2014
November 05, 2014 18:30 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, November 12, 2014 at...
Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
October 27, 2014 16:10 ET
|
Vitae Pharmaceuticals, Inc.
FORT WASHINGTON, Pa., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously...
Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease
October 23, 2014 16:10 ET
|
Vitae Pharmaceuticals, Inc.
BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels
BI1181181/VTP-37948 Was Safe and...